Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies.

In 30 seconds

This post hoc subanalysis of Phase 3 randomized trials evaluated the efficacy, safety, and pharmacokinetics of upadacitinib in East Asian patients with moderately to severely active ulcerative colitis. Results showed that 31.4% of patients achieved clinical remission with upadacitinib at Week 8 compared to 7.3% with placebo, indicating significant efficacy.

Key findings

• 31.4% of East Asian patients achieved clinical remission with upadacitinib at Week 8 compared to 7.3% with placebo.
• At Week 52, 52.4% of patients on upadacitinib 15 mg and 53.8% on 30 mg achieved clinical remission.
• Endoscopic outcomes were significantly higher with upadacitinib compared to placebo across studies.
• No new safety signals were identified, with low occurrences of herpes zoster.

Why it matters

The findings support the use of upadacitinib as an effective treatment option for moderately to severely active ulcerative colitis in East Asian populations, contributing to the understanding of its safety and efficacy in diverse patient groups.